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Drug resistance in malaria parasites represents a major
public health problem in many parts of the world. The disease
affects 400 million people every year and is responsible for 1–2
million deaths a year, mostly among sub-saharan African children (1, 2). Development of new anti-malarials has become an
urgent task, which has stimulated research into the basic biology of Plasmodium falciparum, the species responsible for
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the lethal form of human malaria. We are interested in the
molecular mechanisms controlling the proliferation and the
development of the parasite in the human host, and in this
context we investigate enzymes from the parasite involved in
cell cycle control and signal transduction.
Progression of the eukaryotic cell cycle is controlled by a
family of protein kinases, the cyclin-dependent kinases, whose
active forms are composed of a catalytic subunit (Cdk) and a
regulatory subunit (cyclin). The temporary association of both
subunits results in well defined time windows during which a
given Cdk is active and phosphorylates its substrates at the
appropriate phase of the cell cycle. Several Cdks and cyclins
coexist in eukaryotic cells, with given combinations being responsible for progression of the cell cycle through particular
phases. Cdk䡠cyclin binding is specific in that all cyclins do not
bind indiscriminately to all Cdks. Binding of the cyclin causes
profound changes in the tertiary structure of the kinase, allowing access of the ATP and protein substrates to the catalytic
cleft. A further level of regulation is the phosphorylation status
of the catalytic subunit; in most cases cyclin binding alone
results only in partial activation or no activation at all. Phosphorylation of a threonine residue in the so-called T-loop (Thr160 in human Cdk2) by a Cdk-activating kinase (CAK)1 results
in a further modification of the structure of the catalytic subunit, rendering the enzyme fully active (in some cases, prior
phosphorylation of Thr-160 is required for cyclin binding). In
mammalian cells, the CAK is itself a Cdk, Cdk7, and its activity requires cyclin H (reviewed in Ref. 3–5).
Some Cdks function in cellular processes which are not directly linked with cell cycle control. Thus, Cdk5 has been purified from mammalian brain, where it is involved in the regulation of diverse neuronal functions (6). The Cdk5 kinase
subunit is closely related to other Cdks but its activating partner, p25 (derived by proteolytic cleavage from a 35-kDa precursor), is very different from cyclins at the primary structure
level, although its predicted three-dimensional structure is
similar to that of cyclins (7, 8). p25 is not able to activate other
Cdk subunits such as Cdk1 (cdc2), Cdk2, -3, -4, or -6, and thus
exhibits a narrow specificity toward Cdk5 (9). Another peculiarity of Cdk5 is that it is not activated by Cdk7 like other
mammalian Cdks; instead, it can be activated in vitro by casein
kinase 1 (10).
Cdk homologues have been identified in all eukaryotes
1
The abbreviations used are: CAK, Cdk-activating kinase; crk, cdc2related kinase; ORF, open reading frame; GST, glutathione S-transferase; CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonic acid; HRP, horseradish peroxidase; PDBA, phenylboronic acid;
contig, group of overlapping clones.
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Several Plasmodium falciparum genes encoding cdc2related protein kinases have been identified, but the
modalities of their regulation remains largely unexplored. In the present study, we investigated the regulation in vitro of PfPK5, a putative homologue of Cdk1
(cdc2) in P. falciparum. We show that (i) PfPK5 is efficiently activated by heterologous (human) cyclin H and
p25, a cyclin-like molecule that specifically activates human Cdk5; (ii) the activated enzyme can be inhibited by
chemical Cdk inhibitors; (iii) Pfmrk, a putative P. falciparum homologue of the Cdk-activating kinase, does
neither activate nor phosphorylate PfPK5; and (iv)
PfPK5 is able to autophosphorylate in the presence of a
cyclin. Taken together, these results suggest that the
regulation of Plasmodium Cdks may differ in important
aspects from that of their human counterparts. Furthermore, we cloned an open reading frame encoding a
novel P. falciparum protein possessing maximal homology to cyclin H from various organisms, and we show
that this protein, called Pfcyc-1, is able to activate recombinant PfPK5 in vitro with an efficiency similar to
that of human cyclin H and p25. This work opens the
way to the development of screening procedures aimed
at identifying compounds that specifically target the
parasite Cdks.

Cyclin-dependent Kinases of Malaria Parasites

EXPERIMENTAL PROCEDURES

Molecular Cloning—Oligonucleotides were designed to encompass
the start and the stop codons of the Pfcyc-1 open reading frame (ORF),
which was identified on the contig 19 in the data base of P. falciparum
chromosome 14 (The Institute for Genome Research web site). They
contained BamHI (forward primer: GGGGGGATCCATGAATTATCCAGAAGATAC) and SalI (reverse primer: GGGGGTCGACTTATGATACTTGTAGTTTC) restriction sites near their 5⬘-end. After amplification with a Taq polymerase (Takara), the polymerase chain reaction
product was digested with BamHI and SalI prior to insertion into the
pGEX-4T3 vector. The cloned ORF was verified by DNA sequencing
prior to expression of the recombinant protein.
Expression and Purification of Recombinant Proteins—Expression
and purification of GST-p25 (8), GST-Cdk5 (20), and GST-Pfcyc-1 were
performed as described previously for GST-Pfmap-2 (21). For HisPfPK5, an overnight culture of the bacterial strain SG13009 harboring
the PfPK5 expression construct (12) was diluted 1:50 into 800 ml of 2⫻
YT medium containing 100 g/ml ampicillin and 25 l/ml kanamycin.
When the A600 reached 0.8 –1, expression of PfPK5 was induced by the
addition of isopropyl-␤-thiogalactoside to 0.5 mM, and the culture was
grown for an additional 4 h. Cells were collected by centrifugation at
3600 ⫻ g for 30 min and resuspended in 5 ml of ice-cold sonication
buffer (100 mM Tris-HCl, pH 7.4, 300 mM NaCl, 1 mM dithiothreitol)
containing protease inhibitors (1 mM phenylmethylsulfonyl fluoride
plus the CompleteTM mixture tablet from Roche Molecular Biochemicals) and 100 g/ml lysozyme. After incubation for 10 min on ice, the cell
suspension was sonicated and clarified by centrifugation at 11,300 ⫻ g
for 30 min at 4 °C. The resulting supernatant was applied to 500 l of
packed nickel-nitrilotriacetic acid-agarose beads (Quiagen). After 30
min of incubation at 4 °C, the resin was washed three times with buffer
A (sonication buffer plus 10 mM imidazole), three times with buffer B
(sonication buffer plus 60 mM imidazole), followed by three additional
2
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washes with buffer A. Bound proteins were eluted twice with 250 mM
imidazole in elution buffer (50 mM Tris, pH 8, 400 mM NaCl) and
concentrated in Centricon tubes (Amicon). Pfmrk and human cyclin H
were expressed as polyhistidine fusion proteins in the XL10 GOLD
strain of E. coli (Stratagene) as described above for PfPK5. For purification of these proteins, the cells were centrifuged and resuspended in
a modified sonication buffer (50 mM NaH2PO4, pH 8.0, 300 mM NaCl,
5% glycerol, 1% CHAPS, 10 mM ␤-mercaptoethanol, 10 mM imidazole,
and 1 mM phenylmethylsulfonyl fluoride) containing 1 mg/ml lysozyme.
The procedure was as described above, except that the bound material
was washed using the modified sonication buffer containing 20 mM
imidazole. Pfmrk and human cyclin H were eluted using the same
sonication buffer containing 250 mM imidazole. Protein concentrations
were determined using the Bio-Rad dye reagent according to the manufacturer’s recommendations with bovine serum albumin as a standard, and aliquots of purified proteins were analyzed by SDS-polyacrylamide gel electrophoresis and Coomassie Blue staining.
Kinase Assays—The assays were performed in a standard reaction
(30 l) containing 25 mM Tris-HCl, pH 7.5, 15 mM MgCl2, 2 mM MnCl2
50 M ATP/5 Ci of [␥-32P]ATP, and 5 g of histone H1 (Life Technologies, Inc.). Reactions were initiated by the addition of 0.5 g each of the
recombinant protein kinase and a cyclin partner after both proteins had
been allowed to form a complex at 30 °C for 30 min in kinase assay
buffer. The kinase reaction proceeded for 30 min at 30 °C, and it was
stopped by the addition of Laemmli buffer, boiled for 3 min, and analyzed by electrophoresis on 12% SDS-polyacrylamide gel. The gels were
dried and submitted to autoradiography. Phosphorylation of recombinant protein kinases was assayed in the same conditions but without
histone H1. Data quantification was obtained by densitometric scanning of autoradiograms or by phosphorimaging.
Inhibition Assays—To test the effect of chemical inhibitors on kinase
activity, reactions were performed in the presence of various concentrations of these molecules (stock solutions were at 10 mM in dimethyl
sulfoxide), with the negative controls being reaction mixtures containing only the relevant concentration of solvent. Reactions were performed as described above, except that 15 M ATP/0.05 Ci of
[␥-32P]ATP was used per reaction. 25 l of each reaction were then
spotted onto a small piece of Whatman P81 phosphocellulose paper. The
paper was washed five times in 1% orthophosphoric acid, and the
amount of acid-precipitable radiolabel incorporated in histone H1 was
quantified by scintillation counting.
Detection of Protein-Protein Interactions—PfPK5 polyhistidine fusion
protein complexed with p25-GST was labeled with horseradish peroxidase by using the Linx horseradish peroxidase (HRP) rapid protein
conjugation kit (Invitrogen) as follows: first, PfPK5 (0.5 g/l in phosphate buffered saline, 1 mM EDTA, 1 mM PMSF, pH 7.5) reacted with
phenylboronic acid (PDBA) N-hydroxysuccinimic acid for 1 h at room
temperature. A molar ratio of 14:1 (PDBA-N-hydroxysuccinimic acid:
PfPK5) was used to obtain PDBA-PfPK5, a derivative able to react with
salicylhydroxamic acid-activated peroxidase. PfPK5-PDBA was allowed
to complex with different amounts of (unmodified) p25 diluted in phosphate-buffered saline (30 min, room temperature). Typically, 60 ng of
pfPK5-PDBA reacted with 6 –120 ng of p25. Finally, PfPK5-PDBA䡠p25
complexes reacted with 0.4 g of salicylhydroxamic acid-activated HRP.
Binding of pfPK5 to p25 was demonstrated by a capture enzyme-linked
immunosorbent assay, in which the GST tag of p25 was used for the
capture of the p25䡠PfPK5䡠HRP complexes. A rabbit polyclonal antibody
directed against GST was coated onto enzyme-linked immunosorbent
assay plates (40 g/ml in 50 mM carbonate-bicarbonate buffer, pH 8.5)
and blocked with 5% bovine serum albumin. PfPK5-HRP䡠p25 in phosphate-buffered saline ⫹ 0.5% bovine serum albumin reacted for 30 min
(37 °C) with the coated antibody, the plates were rinsed with phosphate-buffered saline ⫹ 0.05% Tween 20, and bound peroxidase was
revealed by an enzymatic colorimetric reaction using orthophenyenediamine and H2O2 as substrates and quantified at 570 nm in a plate
reader.
RESULTS

Activation of PfPK5 by Mammalian Cyclin H and p25—
Recombinant PfPK5 has been shown to have a very low level
ability to phosphorylate histone H1, a classical Cdk substrate
(12). One of us3 has recently shown that monomeric Pfmrk, a
putative P. falciparum homologue of the Cdk-activating kinase
Cdk7, was able to phosphorylate histone H1, and that this
3

N. Waters, unpublished data.

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on September 24, 2019

where they have been searched for, including malaria parasites. In line with that of other protozoan parasites (11), the
Plasmodium genome contains several genes encoding cdc2related kinase (crk) subunits. The first one to be described was
PfPK5, a putative Cdk1 (cdc2) homologue expressed and active
during erythrocytic schizogony (12, 13). Another kinase of this
group, Pfcrk-1, was subsequently reported as being expressed
specifically in gametocytes (14). PfPK6, an enzyme with high
homology to both Cdks and the related mitogen-activated protein kinases has recently been identified.2 A putative homologue of Cdk7, called Pfmrk, has likewise been characterized in
P. falciparum (15), and the sequences of additional crks have
been identified in the context of the P. falciparum Genome
Project currently under way (for an example, see Ref. 16; for
reviews on the cell cycle and protein kinases in parasites, see
Refs. 17–19).
The precise function of these enzymes in the life cycle of the
parasite still awaits determination. Another point requiring
characterization is that of the biochemical mechanisms pertaining to the regulation of the activity of the Plasmodium crks.
One question in particular comes to mind: do these enzymes
require association with a cyclin-like partner and Thr-160
phosphorylation to become active? Here we report that PfPK5
interacts with mammalian p25, and we show that this interaction is accompanied by a strong stimulation of the kinase
activity even in the absence of phosphorylation by Pfmrk (15),
a P. falciparum CAK putative homologue. Furthermore, comparable activation of PfPK5 can be achieved by using mammalian cyclin H instead of p25. Finally, a P. falciparum sequence
with maximal homology to mammalian cyclin H has been
cloned and expressed in Escherichia coli. The recombinant
protein activates PfPK5 in vitro, in terms of both autophosphorylation and substrate phosphorylation. We used the activated
enzyme to evaluate the effect of kinase inhibitors, a first step
toward the development of a high throughput screening assay
for plasmodial crks.
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FIG. 1. Activation of PfPK5 by human cyclin H. In vitro kinase
assays were performed by adding 0.5 g of the following recombinant
proteins to a reaction mixture containing the radiolabeled ATP and
histone H1 substrates: lane 1, no recombinant protein; lane 2, Pfmrk;
lane 3, Pfmrk and human cyclin H; lane 4, human cyclin H; lane 5,
PfPK5 and human cyclin H; lane 6, Pfmrk and PfPK5; lane 7, PfPK5,
Pfmrk and human cyclin H; lane 8, PfPK5. Top panel, autoradiogram of
the gel; bottom panel, histogram of the CPM values obtained by phosphorimaging of the histone H1 bands in each lane.

histone H1 phosphorylation (lane 7), despite the fact that the
Pfmrk䡠human cyclin H was active, as shown by its ability to
autophosphorylate and to phosphorylate histone H1 (lanes
1–3), as previously reported (see below for a further analysis of
Pfmrk effect on PfPK5 activity).
Cyclin H has 25-fold lower affinity in vitro for other mammalian Cdks than for Cdk7 (23). Because PfPK5 is clearly more
closely related to Cdk1 than to Cdk7, the results described
above suggest that the cyclin partner specificity requirements
may not be as stringent for the plasmodial enzyme as they are
for mammalian Cdks. To test this hypothesis further, we investigated whether or not human p25, whose predicted tertiary
structure is similar to that of cyclins despite a divergent primary structure (7), was able to activate PfPK5. Activation by
p25 is highly specific toward Cdk5; no activation by this protein
was detected on cdc2, Cdk2, Cdk3, Cdk4, or Cdk6 (9). Our
results clearly show that p25 is, unexpectedly, a potent activator of PfPK5 (Fig. 2a, lanes 2– 4). By contrast to human Cdk5,
which responds to p25 (lanes 7 and 8) but not to cyclin H (not
shown), PfPK5 appears to be activated to similar levels by both
proteins. The autophosphorylation and substrate phosphorylation activities of PfPK6, another P. falciparum kinase related
to Cdks and mitogen-activated protein kinases, are unaffected
by p25 (lanes 5 and 6).
Direct Interaction of PfPK5 with p25—Activation of PfPK5 by
p25 is dose-dependent and saturatable (Fig. 2, b and c), which
is consistent with a direct and specific interaction between
these two proteins. To determine whether such a physical
interaction occurs between p25 and PfPK5, we performed an
enzyme-linked immunosorbent assay capture assay using 96well plates coated with an anti-GST antibody. Complexes prepared with various amounts of GST-p25 and a fixed amount of
HRP-conjugated PfPK5 were added to the wells, and the
amount of peroxidase remaining in the wells after washing was
determined. This value increased with the amount of GST-p25
present in the complex sample (Fig. 3). Control wells with no
GST antibody, or with different GST fusion proteins in place of

FIG. 2. PfPK5 activation by p25. a, effect of p25 on the activity of PfPK5, PfPK6, and human Cdk5. In vitro kinase assays were performed by
adding 0.5 g of the following recombinant proteins to a reaction mixture containing the radiolabeled ATP and histone H1 substrates: lane 1, no
recombinant protein; lane 2, human p25; lane 3, PfPK5 and human p25; lane 4, PfPK5; lane 5, PfPK6 and human p25; lane 6, PfPK6; lane 7, human
Cdk5 and p25; lane 8, human Cdk5. b, dose dependence of kinase activity on PfPK5. Kinase assays were performed in the presence of 0.5 g of
human p25 and the indicated amounts of PfPK5, and radiolabel incorporated into histone H1 was measured by scintillation counting after acid
precipitation (see “Experimental Procedures”). c, dose dependence of kinase activity on human p25. Kinase assays were performed in the presence
of 0.5 g of PfPK5 and the indicated amounts of human p25, and radiolabel incorporated into histone H1 was measured as in b. Data in b and c
are from individual experiments, which were repeated with similar results four and three times, respectively.
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basal activity was increased 2-fold in the presence of recombinant human cyclin H (the activating partner of Cdk7) (22). We
wanted to determine whether a mixture of Pfmrk and cyclin H
would result in PfPK5 phosphorylation and activation in vitro.
To this effect, we performed kinase assays with histone H1 as
a substrate, using diverse combinations of PfPK5, Pfmrk, and
human cyclin H. These experiments yielded two unexpected
findings: first, the addition of cyclin H alone to the PfPK5
kinase assay was sufficient to activate PfPK5 to a considerable
level; histone H1 labeling increased up to 1000-fold (Fig. 1,
lanes 5 and 8). This activation factor varied with different
preparations of recombinant proteins and was difficult to measure accurately because of the extremely low level of basal
PfPK5 activity (Fig. 1, lanes 1 and 8). We verified that the
recombinant cyclin H preparation did not contain any intrinsic
kinase activity (lane 4). Second, the addition of Pfmrk to a
reaction containing PfPK5 and human cyclin H appeared not to
cause a significant further increase (other than additive) in

Cyclin-dependent Kinases of Malaria Parasites
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FIG. 3. Detection of PfPK5䡠p25 complexes. An enzyme-linked immunosorbent assay capture assay (see “Experimental Procedures”) was
performed with excess amounts of immobilized anti-GST antibody, a
constant amount of HRP-labeled PfPK5, and various amounts of GSThuman p25. Data are from one out of three experiments that gave
similar results.
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GST-p25, did not give a signal, like the wells where the HRP
was added without PDBA-coupled PfPK5 (see “Experimental
Procedures”). This demonstrates the formation of a PfPK5䡠p25
complex under these experimental conditions.
Inhibition Assays using PfPK5䡠p25 Complexes—Activation of
Cdks by cyclins is achieved through a structural rearrangement of the kinase subunit, leading to the reorientation of the
ATP molecule in the catalytic cleft, allowing phosphotransfer to
occur. The observation that PfPK5 binds to, and is activated by,
p25 strongly suggests that this rearrangement occurs in this
case as well. One can therefore predict that the activity should
be affected by the presence of competitive inhibitors known to
target the ATP-binding pocket (24). To test this hypothesis, we
performed inhibition assays with a few inhibitors of this class
(Fig. 4). Inhibition curves have the expected sigmoid shape and
allow the determination of IC50 values for the compounds. As
could be predicted from the divergence in primary structure
between PfPK5 and mammalian Cdks, the IC50 of individual
compounds is not identical against PfPK5䡠p25 and Cdk1䡠cyclin
B; for indirubin-3⬘-monoxime (25) these values are 10 and 0.2
M, respectively, for purvalanol A (26) they are 8 and 0.004 M,
and for hymenialdisine-01 (27) they are 1 and 0.02 M.
Cloning and Expression of a P. falciparum Cyclin and Its
Ability to Activate PfPK5—No cyclin structural (or functional)
homologue has yet been described in malaria parasites, but it
can be expected that progress of the P. falciparum Genome
Project will shed light on this issue. Indeed, while the experiments described above were in progress, we performed a
BLAST analysis of the Project data bases, using mammalian
cyclins as search sequences. This led us to identify a contig
from chromosome 14 carrying an ORF with a BLAST score that
warranted further investigation (see Fig. 5a). BLAST analysis
on the NRprot data base indicated that this ORF was indeed
closely related to cyclins, the highest scores being with cyclin H
from various organisms. However, the homology was very weak
and restricted to a small number of regions of a few amino acids
(see Fig. 5b for an alignment). The ORF was flanked on both
sides by homopolymeric stretches of adenosine and thymidine
residues that are characteristic of P. falciparum noncoding
regions (Fig. 5a). Together with the fact that stop codons can be
found in all three frames over several hundred base pairs just
outside the ORF, this suggests that the latter represents the
entire coding region of one polypeptide. The coding sequence
was amplified from a P. falciparum cDNA library and cloned
into the pGEX expression plasmid. After DNA sequence verification, a recombinant protein was produced, purified, and
added to in vitro kinase assays to determine whether it was
able to activate PfPK5 (Fig. 6). Clearly, this protein, which we
call Pfcyc-1, is able to stimulate PfPK5 as efficiently as human

FIG. 4. Inhibition of PfPK5䡠p25 activity by Cdk inhibitors. Indicated amounts of each inhibitor (top, hymenialdisine 01 (HD01);
middle, indirubin-3⬘-monoxime (I3M); bottom, purvalanol A) were
added to in vitro kinase assays using histone H1 as a substrate with 0.5
g each of PfPK5 and human p25. The inhibitors were diluted in Me2SO
in such a way that an equal volume of the solvent was added to all
reactions. Values are expressed as the percentage of the activity measured in the absence of inhibitor. The same IC50 values have been found
in two sets of experiments, each done in duplicate; data in the figure
represent the average values from one of these experiments.

cyclin H or p25. We also repeatedly observed low level labeling
of an additional band that we attributed to the cyclin subunit
(GST-Pfcyc-1, GST-p25, or human cyclin H) when PfPK5 was
present (not shown).
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FIG. 5. a. Sequence of the region of
contig 19 from P. falciparum chromosome 14 encompassing the Pfcyc-1
ORF. Stop and start codons are indicated
in bold, and the sequences used for amplification primers are underlined. By
comparison with the contig sequence, the
fragment we amplified from 3D7 DNA
had one discrepancy underlined in the figure; the codon for amino acid 225 is AAG
in the contig and AGG in the amplified
fragment, resulting in change from a lysine to arginine. This arginine is conserved in cyclin H from other organisms
(see b). b, alignment of the deduced amino
acid sequence of the Pfcyc-1 ORF with the
cyclin H sequences from Homo sapiens
and Xenopus laevis. The arginine residue
discussed above is underlined.

Absence of PfPK5 or PfPK6 Stimulation by Pfmrk䡠Pfcyc-1
and Autophosphorylation of PfPK5 in the Presence of Pfcyc1—As Pfcyc-1 is most closely related to cyclin H, which activates the CAKs in other eukaryotes, and as Pfmrk is a putative
CAK homologue, we naturally wanted to determine whether
the homologous pair Pfmrk䡠Pfcyc-1 would activate plasmodial
crks (we have shown (Fig. 1) that the heterologous pair

Pfmrk䡠human cyclin H did not stimulate PfPK5 activity, but
this might conceivably have been because of the heterologous
origin of the cyclin). Results of these experiments (not shown,
as they mirror the data presented in Fig. 1) indicate that the
properties of Pfcyc-1, in terms of its effect on Pfmrk, PfPK5,
and PfPK6 activities, are essentially undistinguishable from
those of human cyclin H: (i) Pfcyc-1 stimulates histone H1

Cyclin-dependent Kinases of Malaria Parasites

FIG. 6. In vitro activity of Pfcyc-1. In vitro kinase assays were
performed by adding 0.5 g of the following recombinant proteins to a
reaction mixture containing the radiolabeled ATP and histone H1 substrates: lane 1, no recombinant protein; lane 2, Pfcyc-1; lane 3, human
cyclin H; lane 4, PfPK5; lane 5, PfPK5 and Pfcyc-1; lane 6, PfPK5 and
human cyclin H.

DISCUSSION

Malaria parasites are not easily amenable to investigations
concerning gene function because of the difficulties associated
with both classical and reverse genetics approaches in the
study of these organisms. The problem is particularly acute
with respect to genes that are essential for the erythrocytic
asexual cycle, because in available protocols for the generation
of null mutants selection of transformed parasites occurs at
this stage; this makes it impossible to target a gene required for
this process (28). For these reasons, investigations on processes
such as cell cycle progression in Plasmodium have relied
mainly on phenomenological observations and on the cloning
and biochemical characterization of the putative homologues of
genes involved in cell cycle control in other eukaryotes. This
lead on one hand to the description of peculiarities in the cell
division process during schizogony, such as crypto-orthomitosis
(the maintenance of the nuclear membrane during division)
and apparent asynchrony in the division of nuclei within a
schizont, and on the other hand to the identification of several
genes encoding putative cell cycle regulators (a complete repertoire of such genes will become available as the P. falciparum

FIG. 7. Autophosphorylation of PfPK5 in the presence of Pfcyc-1. In vitro kinase assays were performed by adding 0.5 g of
recombinant proteins to a reaction mixture containing radiolabeled
ATP; histone H1 was added in lanes 1–5 but omitted in lanes 6 and 7.
Lane 1, no recombinant protein; lane 2, Pfcyc-1; lane 3, PfPK5; lane 4,
Pfmrk; lane 5, PfPK5 and Pfcyc-1; lane 6, PfPK5 and Pfcyc-1 (no
histone); lane 7, PfPK5, Pfcyc-1 and Pfmrk (no histone).

Genome Project nears completion) (reviewed in Refs. 17–18).
An obvious task is the integration of these lines of approaches
into a coherent picture of Plasmodium cell cycle regulation.
This forms the context of the present study, which addresses
the question of the regulation of P. falciparum crks.
Although several plasmodial crks have been identified over
the last few years, important questions regarding their function and regulation still require solving. How similar to that of
other eukaryotes are the modalities of Plasmodium crk regulation? This question has recently been addressed in trypanosomatids, another group of protozoan parasites, and it was
shown that mammalian cyclins can interact with a Trypanosoma cruzi crk (29). Here, we show not only that such an
interaction also occurs between a mammalian cyclin-like protein and PfPK5, a plasmodial putative Cdk1 homologue, but
also that this interaction is accompanied by a strong stimulation of PfPK5 kinase activity. PfPK5 is clearly much more
closely related to Cdk1 than to Cdk7 (60% identity at the amino
acid level with human Cdk1 (12) compared with 35% with
Cdk7). Hence the observation that it can be efficiently activated by human cyclin H, which is the activating partner of
Cdk7, is unexpected. Also surprising was the observation that
human p25 is likewise able to activate PfPK5. That it is unexpected does not arise in this case from considerations about the
relatedness between the PfPK5 and the Cdk5 sequences; indeed, PfPK5 turns out to be as closely related, in terms of
overall sequence similarity, to human Cdk5 as it is to human
Cdk1 (approximately 60% identity in both cases). Instead, the
surprise comes from the fact that PfPK5 is activated equally
efficiently by two molecules, cyclin H and p25, which in higher
eukaryotes activate different catalytic subunits. By contrast, in
mammalian cells p25 shows a stringent specificity toward
Cdk5 (9) and to our knowledge does not activate other members
of the Cdk family. This specificity is at least partially symmetrical, as other cyclins do not activate Cdk5 (in our experiments,
Cdk5 activity does not respond to human cyclin H or Pfcyc-1).
Incidentally, this suggests that PfPK5 is not the P. falciparum
orthologue of Cdk1 as previously thought but might instead be
a homologue of Cdk5; this is corroborated by our observation
that a BLAST search with the PfPK5 amino acid sequence on
the Caenorhabditis elegans (whose entire complement of Cdks
has been characterized) data base gives the putative C. elegans
Cdk5 homologue as the highest scoring entry (57% identity)
before the Cdk1 homologue (53% identity). Nevertheless, taken
together our results tend to suggest that PfPK5 may be activated by cyclins in vitro in a way that is more promiscuous than
mammalian Cdks; could it be that any protein with a cyclinlike tertiary structure is able to activate this kinase? We are
planning now to test this hypothesis further, using a larger
complement of both heterologous and (as they become available
from the P. falciparum genome data base) Plasmodium cyclins.
It is worth mentioning here the ability of Pho85 (a Saccharomyces cerevisiae Cdk) to be activated by several different cyclins, which confers to this enzyme a large diversity of functions
(30, 31). This aspect of plasmodial Cdk regulation would thus
appear to resemble what is found in other lower eukaryotes.
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phosphorylation by Pfmrk about 2-fold, like human cyclin H
does; this effect is small in comparison with that of the human
and plasmodial cyclins on PfPK5, where the activation factor is
up to three orders of magnitude higher; (ii) the simultaneous
presence of Pfcyc-1, Pfmrk, and PfPK5 does not result in a
synergistic increase of H1 phosphorylation; and (iii) PfPK6 is
not activated by incubation with either Pfmrk䡠Pfcyc-1 or Pfcyc-1 alone (although we sometimes observed a very small
increase of PFPK6 activity (less than 2-fold) in the presence of
human cyclin H).
To check whether the lack of synergy between PfPK5 and
Pfmrk in the presence of cyclin H was not due simply to a
saturation effect, dose-dependent experiments were performed
where the effect of variations in the concentration of each
kinase on histone H1 phosphorylation was evaluated. These
experiments (not shown) confirmed the apparent lack of synergistic activities of PfPK5 and Pfmrk. A more direct way of
determining whether Pfmrk can phosphorylate PfPK5 is to
measure 32P incorporation in the latter enzyme in the presence
of Pfmrk. As PfPK5 migrates very close to phosphorylated
histone H1 in polyacrylamide gels, it is difficult to assess the
phosphorylation status of the kinase in the presence of the
substrate. Therefore, we performed kinase reactions containing
diverse combinations of Pfmrk, Pfcyc-1, and PfPK5, without
adding histone H1 (Fig. 7). The most striking result of this
experiment is that PfPK5䡠Pfcyc-1 is able to autophosphorylate
on the kinase subunit (lanes 6 and 7); the GST-Pfcyc-1 recombinant protein, which is much larger (around 60 kDa) than the
kinase subunit, was also labeled, to a lower extent than PfPK5.
Furthermore, it appears clearly that the addition of Pfmrk does
not cause an increase in PfPK5 labeling; on the contrary, we
observed a decrease of PfPK5 phosphorylation when Pfrmrk
was present (lane 7). This is presumably because of competition
for Pfcyc-1 between the two kinase subunits.
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and its yeast homologue CDC28 have different sensitivities to
a given inhibitor (26). Our data indicating that PfPK5䡠cyclin
complexes can be used to measure the IC50 of inhibitors pave
the way for the development of efficient screening systems
aimed at identifying molecules with a specific effect on parasite-encoded kinases, which can then be assayed for ex vivo
antimalarial activity.
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Full activation of most Cdk䡠cyclin complexes requires phosphorylation of the T-loop threonine (Thr-160 in human Cdk2)
by Cdk7䡠cyclin H, the Cdk-activating kinase. Our experiments
show that Pfmrk, a putative homologue of Cdk7, does not
activate nor phosphorylate PfPK5, even in the presence of
human cyclin H. This is not because of the heterologous (human) origin of the cyclin, because replacing human cyclin H
with Pfcyc-1 (a P. falciparum protein with maximal homology
to cyclin H from various organisms) does not confer activity to
Pfmrk. Several possible explanations come to mind: first,
Pfmrk may have specific CAK activity on other plasmodial
crks; Pfmrk mRNA is more abundant in gametocytes than in
asexual parasites, and it is conceivable that it activates some
crk different from PfPK5 and present in gametocytes, Pfcrk-1
for example (14). Second, Pfmrk may require another cyclin
partner (i.e. different from Pfcyc-1) or additional parasite-derived proteins to show CAK activity on PfPK5; in mammalian
cells, the majority of Cdk7䡠cyclin H complexes are found in
association with a third protein, Mat1 (5, 32). Third, Pfmrk
may not be a CAK at all. In S. cerevisiae, the closest relative of
Cdk7 (Kin28) is required for RNA polymerase II-dependent
transcription and associates with TFIIH, but does not possess
CAK activity (3, 5, 33). In this organism CAK activity is provided by Cak1, a kinase unrelated to Cdk7 and that does not
require association with activating partners (34).
Although PfPK5 is not a substrate for Pfmrk, it nevertheless
becomes phosphorylated in the presence of Pfcyc-1. To our
knowledge, such Cdk autophosphorylation has not been documented in other organisms. A very low level autophosphorylation of PfPK5 has been detected in the absence of a cyclin
partner (12, 35), but available data are not sufficient to determine whether the same residues are phosphorylated in both
cases. It will be interesting to find whether cyclin binding
results in autophosphorylation of the T-loop threonine (Thr158 in PfPK5 corresponding to Thr-160 in human Cdk2). If this
were shown to be the case, it would argue in favor of a model of
PfPK5 regulation where CAK activity provided by a different
kinase would not be required.
Hence the regulation of PfPK5 appears to be notably different from that of its homologues found in higher eukaryotes in
that (i) the enzyme seems to be activable by a wider range of
cyclin䡠cyclin-like partners; (ii) when in conjunction with such a
partner, it is able to undergo autophosphorylation; and (iii)
considerable activation is achieved in the absence of a CAK in
vitro (the latter property is shared by some Cdk䡠cyclin pairs of
higher eukaryotes, e.g. Cdk2䡠cyclin A (36)). Obviously one cannot exclude at this stage that Pfmrk or yet another enzyme
activates PfPK5 by phosphorylation in vivo.
It is likely that Pfcyc-1 is only one member of a family of P.
falciparum cyclin-like proteins. It will soon become possible to
address the question of specificity in Plasmodium crk䡠cyclin
interactions and to gain information of the temporal expression
of these elements during parasite development. It is hoped that
this will contribute significantly to the emergence of a better
understood picture of cell cycle control in this organism.
Because of the crucial role they are most likely to play in the
control of cell division and/or development, plasmodial crks
represent attractive potential targets for novel antimalarial
agents. Our data (Fig. 4) are consistent with the idea that
sequence divergences between parasite crks and human Cdks
are likely to result in different affinities for inhibitory molecules. This is supported by the observation that human Cdk1

Activation of a Plasmodium falciparum cdc2-related Kinase by Heterologous p25 and
Cyclin H: FUNCTIONAL CHARACTERIZATION OF A P. FALCIPARUM
CYCLIN HOMOLOGUE
Karine Le Roch, Claude Sestier, Dominique Dorin, Norman Waters, Barbara Kappes,
Debopam Chakrabarti, Laurent Meijer and Christian Doerig
J. Biol. Chem. 2000, 275:8952-8958.
doi: 10.1074/jbc.275.12.8952

Access the most updated version of this article at http://www.jbc.org/content/275/12/8952

Click here to choose from all of JBC's e-mail alerts
This article cites 34 references, 9 of which can be accessed free at
http://www.jbc.org/content/275/12/8952.full.html#ref-list-1

Downloaded from http://www.jbc.org/ at UCF Health Sciences Library on September 24, 2019

Alerts:
• When this article is cited
• When a correction for this article is posted

